This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Theratechnologies Inc.. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: The Innovations of Daniel Fleury
Introduction
Daniel Fleury is an accomplished inventor based in Saint-Hubert, Canada. He has made significant contributions to the field of pharmaceutical formulations, particularly in the area of growth hormone releasing factors.
Latest Patents
Fleury holds a patent for "Formulations of growth hormone releasing factor (GRF) molecules with improved stability." This patent includes stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as an active ingredient. The formulations feature GRF analogs, including those with an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a β-cyclodextrin that is not conjugated to the GRF molecule or its salt. The patent also discloses methods for stabilizing GRF molecules and inhibiting their deamidation at Asn.
Career Highlights
Fleury is associated with Theratechnologies Inc., a company that focuses on developing innovative therapies for various medical conditions. His work has contributed to advancements in pharmaceutical formulations that enhance the stability and efficacy of growth hormone releasing factors.
Collaborations
Fleury collaborates with Kirill I Shingel, who is also involved in the research and development of pharmaceutical innovations.
Conclusion
Daniel Fleury's contributions to the field of pharmaceutical formulations demonstrate his commitment to advancing medical science. His innovative work on growth hormone releasing factors has the potential to improve treatment options for various conditions.